Results for this period
First quarter1 January 2026–31 March 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Lower sales, mainly of COVID-19 genetic testing kits and tests for other infectious diseases
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 January 2026–31 March 2026 |
| Net Sales | ¥2,208 million (YoY -16.7%) |
| Operating profit | ¥759 million (YoY -32.3%) |
| Ordinary income | ¥823 million (YoY -22.6%) |
| Profit attributable to owners of the parent | ¥601 million (YoY -22.6%) |
| Net income per share | ¥31.57 |
| Equity ratio | End of the current fiscal period 87.6 / End of previous period 83.5 |
| Total assets | ¥20,934 million |
| Net assets | ¥18,333 million |
| Full-year earnings forecast | Net Sales ¥11,428 million (YoY +1.5%) / Operating profit ¥4,414 million (YoY -5.0%) / Ordinary income ¥4,437 million (YoY -6.3%) / Net income ¥3,220 million (YoY -6.0%) |
| Annual Dividend Forecast | ¥100 → ¥100（0.0%） |
| Depreciation and amortization | ¥69 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 19,051,200 shares |
| Treasury Shares at Period-End | 2,550 shares |
| Factors Behind Changes in Business Performance | Lower sales, mainly of COVID-19 genetic testing kits and tests for other infectious diseases |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Operating profit declined mainly because of lower sales of COVID-19 genetic testing kits and tests for other infectious diseases. The company attributed this to the reduced scale of COVID-19 outbreaks and the fact that outbreaks of other infectious diseases were not as widespread as in the previous year.